Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498390 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL865529 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL29437011 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL18045565 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL18045584 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL5069212 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL29498395 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL18045563 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL18045545 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 | |
| SCHEMBL29508345 | 1.00 | TSHR (0.82) | TSHRCYP3A4TP53MAOBPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140174801-A1 | CONDUCTIVE MATERIAL AND PROCESS | Henkel IP & Holding GmbH (DE) | 2014-06-26 | — | — | US | claimed |
| WO-2013036523-A1 | CONDUCTIVE MATERIAL AND PROCESS | HENKEL CORPORATION (US) | 2013-03-14 | — | — | WO | claimed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | claimed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | claimed |
| WO-2026100662-A1 | LIQUID CRYSTAL ALIGNING AGENT AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2025127092-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2025-06-19 | — | — | WO | disclosed |
| US-20250180952-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-06-05 | — | — | US | disclosed |
| US-20250145888-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | NISSAN CHEMICAL CORPORATION (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-4528369-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY ELEMENT | Nissan Chemical Corporation (JP) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025033304-A1 | METHOD FOR MANUFACTURING LIQUID CRYSTAL ALIGNMENT FILM, AND METHOD FOR MANUFACTURING LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2025-02-13 | — | — | WO | disclosed |
| EP-4493638-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-01-22 | — | — | EP | disclosed |
| EP-4481484-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | Nissan Chemical Corporation (JP) | 2024-12-25 | — | — | EP | disclosed |
| US-20100048849-A1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | ROLIC AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080293888-A1 | Photocrosslinkable Materials | ROLIC AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-6143917-A | FROM A DIARYL CARBONATE AND AN AMINE COMPOUND HAVING AT LEAST ONE HYDROGEN ATOM LOCATED AT AN N-POSITION UNDER MODERATE CONDITIONS AT A HIGH REACTION RATE WITH A HIGH SELECTIVITY AND WITH A HIGH YIELD | UBE INDUSTRIES, LTD. (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0902014-A1 | PROCESS FOR PRODUCING ARYL CARBAMATES | UBE INDUSTRIES LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |
| US-4769439-A | Polyimides and method for making | GENERAL ELECTRIC COMPANY (US) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | TSHR 1346/4885CYP3A4 403/4885TP53 3415/4885 |
| US-20100048849-A1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | DDC, ALAD, DYNC1LI1 | TSHR 4828/4885CYP3A4 4068/4885TP53 3868/4885 |
| US-20080293888-A1 | Photocrosslinkable Materials | DDC, PARG, ALAD | TSHR 3933/4885CYP3A4 4202/4885TP53 4305/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | TSHR 4634/4885CYP3A4 1342/4885TP53 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.